Category: MS Research Study and Reports

Featured image for “Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)”

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)

April 17, 2024 Download PDF New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis…

Stuart Schlossman

Featured image for “Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis”

Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis

Apr 17, 2024 EAST HANOVER, N.J., April 17, 2024 — Novartis today announced data from the ALITHIOS open-label extension study showing sustained…

Stuart Schlossman

Apr 16, 2024 – Press Release: Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Media / Press Releases Tuesday, Apr 16, 2024 Results from the Phase III study showed that subcutaneous (SC) injection was consistent with…

Stuart Schlossman

Redefining Relapse in Efficacy Measures for Multiple Sclerosis Treatments

By: Stephen Krieger, MD; Enrique Alvarez, MD, PhD In this poster, Enrique Alvarez, MD, PhD., (from university of Colorado at…

Stuart Schlossman

Featured image for “Will Frexalimab replace the anti-CD20s?”

Will Frexalimab replace the anti-CD20s?

It is clear to me, and it should be clear to my colleagues, that anti-CD20 therapies have a limited shelf-life…

Stuart Schlossman

Dark rim on MS lesions seen with standard MRI may mark activity

Possible way of spotting in clinic rim lesions known to drive progression By Marisa Wexler, MS on 02/26/2024 An imaging…

Stuart Schlossman

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS (sanofi.com)

 Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS Paris, February 15, 2024. The…

Stuart Schlossman

Nitric oxide metabolites in blood could aid diagnosis of MS: Study

Molecules were elevated in study of RRMS, PPMS patients by Lindsey Shapiro, PhD | February 13, 2024 Measuring levels of nitric oxide metabolites…

Stuart Schlossman

Ancient DNA From Eurasian Herders Sheds Light on the Origins of Multiple Sclerosis

 January 14, 2014 Genetic variants linked to the risk of MS were brought to Europe during a migration around 5,000…

Stuart Schlossman

Blood levels of GFAP protein may predict disease progression in PPMS

 Risk of disability worsening nearly 3 times greater with high GFAP: Study The ongoing worsening of disability among people with primary…

Stuart Schlossman

Categories

Latest Blog Posts